Literature DB >> 10228290

Left vagal nerve stimulation in children with medically refractory epilepsy. The Pediatric VNS Study Group.

J V Murphy1.   

Abstract

OBJECTIVE: To assess the use of intermittent left vagal nerve stimulation in a large population of children with pharmacoresistant epilepsy. STUDY
DESIGN: Sixty children who were entered into controlled or compassionate use protocols of left vagal nerve stimulation all had been monitored for at least 3 months after their left vagal nerve stimulators were activated.
RESULTS: The age range was 3 to 18 years (median 15 years). Sixteen of these 60 patients were younger than 12 years. Fifty-seven percent of the patients had partial complex seizures, and generalized tonic clonic seizures occurred in 27%. After 3 months of intermittent stimulation of the left vagal nerve, a median reduction in seizure frequency of 23% occurred in 60 patients. At 6 months the median reduction was 31% in 55 patients, at 12 months 34% in 51 patients, and at 18 months 42% in 46 patients. Improvement was not associated with any seizure type or seizure cause. Adverse events during stimulation included fever, coughing, colds, and voice alteration. None of these necessitated cessation of stimulation. Complications included aspiration pneumonia and necrosis of skin overlying the generator.
CONCLUSIONS: Intermittent stimulation of the left vagal nerve appears to be a safe, adjunctive therapy for the treatment of children with epilepsy intractable to available antiepileptic drugs. The reduction in seizure frequency in children was similar to that reported in adults.

Entities:  

Mesh:

Year:  1999        PMID: 10228290     DOI: 10.1016/s0022-3476(99)70241-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  24 in total

Review 1.  Neurostimulation therapy for epilepsy.

Authors:  Douglas Labar; Andy Dean
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

2.  Vagal nerve stimulation for pharmacoresistant epilepsy in children.

Authors:  Jason S Hauptman; Gary W Mathern
Journal:  Surg Neurol Int       Date:  2012-10-31

3.  Vagus Nerve Stimulation As Treatment for Epileptic Seizures.

Authors:  Martin C. Salinsky
Journal:  Curr Treat Options Neurol       Date:  2003-03       Impact factor: 3.598

Review 4.  Pre-surgical evaluation and surgical treatment in children with extratemporal epilepsy.

Authors:  Ricardo Silva Centeno; Elza Marcia Yacubian; Americo Ceiki Sakamoto; Antonio Fernando Patriani Ferraz; Henrique Carrete Junior; Sergio Cavalheiro
Journal:  Childs Nerv Syst       Date:  2006-07-11       Impact factor: 1.475

5.  Long-term results of vagus nerve stimulation in children and adolescents with drug-resistant epilepsy.

Authors:  Beata Majkowska-Zwolińska; Piotr Zwoliński; Marcin Roszkowski; Krzysztof Drabik
Journal:  Childs Nerv Syst       Date:  2012-01-06       Impact factor: 1.475

6.  Meta-analysis of vagus nerve stimulation treatment for epilepsy: correlation between device setting parameters and acute response.

Authors:  S Ghani; J Vilensky; B Turner; R S Tubbs; M Loukas
Journal:  Childs Nerv Syst       Date:  2015-10-22       Impact factor: 1.475

Review 7.  Vagus nerve stimulation for epilepsy and depression.

Authors:  Andrew H Milby; Casey H Halpern; Gordon H Baltuch
Journal:  Neurotherapeutics       Date:  2008-01       Impact factor: 7.620

Review 8.  Vagus nerve stimulation: can it be used in adolescents or children with treatment-resistant depression?

Authors:  Zheya Jenny Yu; Ronald A Weller; Kendra Sandidge; Elizabeth B Weller
Journal:  Curr Psychiatry Rep       Date:  2008-04       Impact factor: 5.285

Review 9.  Treatment of partial seizures in childhood : an overview.

Authors:  Giangennaro Coppola
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

10.  Complications of vagal nerve stimulation for epilepsy in children.

Authors:  F Rychlicki; N Zamponi; E Cesaroni; L Corpaci; R Trignani; A Ducati; M Scerrati
Journal:  Neurosurg Rev       Date:  2006-02-18       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.